Merck and Mersana Therapeutics to co-develop new immunostimulatory ADCs

Merck has announced a collaboration with US-based Mersana Therapeutics to discover new antibody-drug conjugates (ADCs) by leveraging the latter’s proprietary Immunosynthen STING-agonist ADC platform. The ... Read More